Skip to main content

Clinical studies are our business strategy to bring the newest approaches, both in diagnostic and therapeutic techniques, to our patients. With this goal in mind, we have been working to increase our capacity to face a higher number of clinical trials, even more complex, growing in the last five years, from 1000 to almost 2000 last year in the whole Vall d’Hebron Campus (VHIR and VHIO).

More than 2800 participants were enrolled in 2021. More than a half of these trials were in early phases, phase one or phase two.

Clinical trials allow us to reach pharma industry confidence in very critical projects, to get a very high an immediate impact on patient life and health, and to give back society with transparency and credibility.

Most relevant clinical studies in 2021 conducted by VHIR researchers:

  • Vaccines against COVID-19 with different pharmaceuticals such as Pfizer-BioNTech, Janssen and Hipra.
  • Within the field of gene therapy, we highlight the trials on Spinal Muscular Atrophy or Duchenne Muscular Dystrophy.
  • A phase I trial with Ceritinib for childhood cancer with malignant tumors (large cell anaplastic lymphoma, neuroblastoma, rhabdomyosarcoma or inflammatory myofibroblastic tumor).
  • A Phase III international clinical trial with dupilumab to control moderate and severe childhood asthma. Based on the results, the European Medicines Agency (EMA) has approved the use of this monoclonal antibody in asthmatic patients from the age of six.
  • A clinical trial (BP39055) for a Parkinson’s treatment which proved effective in the early stages of the disease.

Leave a Reply

VHIR Annual Report 2021